These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37733830)

  • 1. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.
    Ali LR; Lenehan PJ; Cardot-Ruffino V; Dias Costa A; Katz MHG; Bauer TW; Nowak JA; Wolpin BM; Abrams TA; Patel A; Clancy TE; Wang J; Mancias JD; Reilley MJ; Stucky CH; Bekaii-Saab TS; Elias R; Merchant N; Slingluff CL; Rahma OE; Dougan SK
    Clin Cancer Res; 2024 Feb; 30(3):542-553. PubMed ID: 37733830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome-based identification of tumor-reactive and bystander CD8
    Meng Z; Rodriguez Ehrenfried A; Tan CL; Steffens LK; Kehm H; Zens S; Lauenstein C; Paul A; Schwab M; Förster JD; Salek M; Riemer AB; Wu H; Eckert C; Leonhardt CS; Strobel O; Volkmar M; Poschke I; Offringa R
    Sci Transl Med; 2023 Nov; 15(722):eadh9562. PubMed ID: 37967201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
    Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
    BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
    Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization of CD8
    Seo YD; Jiang X; Sullivan KM; Jalikis FG; Smythe KS; Abbasi A; Vignali M; Park JO; Daniel SK; Pollack SM; Kim TS; Yeung R; Crispe IN; Pierce RH; Robins H; Pillarisetty VG
    Clin Cancer Res; 2019 Jul; 25(13):3934-3945. PubMed ID: 30940657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
    Zhang J; Ji Z; Caushi JX; El Asmar M; Anagnostou V; Cottrell TR; Chan HY; Suri P; Guo H; Merghoub T; Chaft JE; Reuss JE; Tam AJ; Blosser RL; Abu-Akeel M; Sidhom JW; Zhao N; Ha JS; Jones DR; Marrone KA; Naidoo J; Gabrielson E; Taube JM; Velculescu VE; Brahmer JR; Housseau F; Hellmann MD; Forde PM; Pardoll DM; Ji H; Smith KN
    Clin Cancer Res; 2020 Mar; 26(6):1327-1337. PubMed ID: 31754049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
    Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
    Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
    Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
    Front Immunol; 2021; 12():730746. PubMed ID: 34630409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
    Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
    Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
    Nagasaki J; Inozume T; Sax N; Ariyasu R; Ishikawa M; Yamashita K; Kawazu M; Ueno T; Irie T; Tanji E; Morinaga T; Honobe A; Ohnuma T; Yoshino M; Iwata T; Kawase K; Sasaki K; Hanazawa T; Kochin V; Kawamura T; Matsue H; Hino M; Mano H; Suzuki Y; Nishikawa H; Togashi Y
    Cell Rep; 2022 Feb; 38(5):110331. PubMed ID: 35108529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens.
    Brugiapaglia S; Bulfamante S; Curcio C; Arigoni M; Calogero R; Bonello L; Genuardi E; Spadi R; Satolli MA; Campra D; Giordano D; Cappello P; Cordero F; Novelli F
    Front Immunol; 2024; 15():1427424. PubMed ID: 39176093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.